Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.

[1]  M. Mendelsohn,et al.  Protective effects of estrogen on the cardiovascular system. , 1999, The American journal of cardiology.

[2]  D. Reboussin,et al.  The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. , 2000, Controlled clinical trials.

[3]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[4]  V. Hombach,et al.  Effect of 17-beta estradiol on pre-existing atherosclerotic lesions: role of the endothelium. , 1999, Atherosclerosis.

[5]  M. R. Andersen,et al.  The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. , 1999, Circulation.

[6]  D. Herrington.  The HERS Trial Results: Paradigms Lost? , 1999, Annals of Internal Medicine.

[7]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[8]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[9]  C. Stehouwer,et al.  Increased C-reactive Protein Levels during Short-term Hormone Replacement Therapy in Healthy Postmenopausal Women , 1999, Thrombosis and Haemostasis.

[10]  L. Kuller,et al.  Hormone replacement therapy, inflammation, and hemostasis in elderly women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[11]  V. Beral,et al.  Hormone replacement therapy for secondary prevention of coronary heart disease. , 1999, JAMA.

[12]  T. Bush.  Lessons from HERS: the null and beyond. , 1998, Journal of women's health.

[13]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[14]  S B Hulley,et al.  Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. , 1998, Controlled clinical trials.

[15]  B. G. Brown,et al.  Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction A 10-year Familial Atherosclerosis Treatment Study follow-up , 1998 .

[16]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[17]  H. Krumholz,et al.  Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. , 1997, Circulation.

[18]  J. Manson,et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.

[19]  R H Selzer,et al.  Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. , 1996, Circulation.

[20]  W. Cascio,et al.  The Ib phase of ventricular arrhythmias in ischemic in situ porcine heart is related to changes in cell-to-cell electrical coupling. Experimental Cardiology Group, University of North Carolina. , 1995, Circulation.

[21]  V. Fuster,et al.  Preventing heart attack and death in patients with coronary disease. , 1995, Circulation.

[22]  P. Ganz,et al.  How do we explain the clinical benefits of estrogen? From bedside to bench. , 1995, Circulation.

[23]  D. Herrington,et al.  Regression of atherosclerosis in female monkeys. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[24]  S. Grundy,et al.  National Cholesterol Education Program, second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. , 1995 .

[25]  L. Wilkins,et al.  National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994, Circulation.

[26]  T. Craven,et al.  Prognostic Significance of Progression of Coronary Atherosclerosis , 1993, Circulation.

[27]  Caroline S. Fox,et al.  Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.

[28]  M. Sanmarco,et al.  Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. , 1992, JAMA.

[29]  E. Alderman,et al.  Coronary artery quantitation and data management system for paired cineangiograms. , 1991, Catheterization and cardiovascular diagnosis.

[30]  C. Christiansen,et al.  Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. , 1991, The Journal of clinical investigation.

[31]  S. Manuck,et al.  Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. , 1990, Arteriosclerosis.

[32]  K. Gould,et al.  Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial , 1990, The Lancet.

[33]  A. Yeung,et al.  Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. , 1990, Circulation.